Shares of XBiotech Inc. (NASDAQ:XBIT - Get Free Report) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.88 and traded as low as $2.85. XBiotech shares last traded at $2.90, with a volume of 40,915 shares.
XBiotech Price Performance
The stock has a 50 day moving average price of $2.88 and a 200-day moving average price of $3.08. The stock has a market capitalization of $86.74 million, a price-to-earnings ratio of -2.21 and a beta of 0.97.
XBiotech (NASDAQ:XBIT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On XBiotech
A number of large investors have recently bought and sold shares of XBIT. Hsbc Holdings PLC purchased a new stake in XBiotech in the 1st quarter worth approximately $52,000. JPMorgan Chase & Co. grew its stake in shares of XBiotech by 68.2% during the 4th quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock valued at $58,000 after buying an additional 5,930 shares during the period. Bank of America Corp DE raised its holdings in shares of XBiotech by 42.0% in the 4th quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock worth $79,000 after purchasing an additional 5,887 shares during the period. Nuveen LLC purchased a new stake in XBiotech during the first quarter worth approximately $81,000. Finally, Barclays PLC increased its holdings in XBiotech by 13.9% in the 4th quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock valued at $119,000 after purchasing an additional 3,661 shares in the last quarter. Hedge funds and other institutional investors own 55.70% of the company's stock.
About XBiotech
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
See Also
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access